{
    "nct_id": "NCT03663335",
    "official_title": "A Partially-blinded, Active-controlled, Multicenter, Randomized Study Evaluating Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in de Novo and Maintenance Kidney Transplant Recipients (CIRRUS I)",
    "inclusion_criteria": "* Written informed consent obtained before any assessment.\n* Male or female patient â‰¥ 18 years old.\n* Up to date vaccination as per local immunization schedules.\n* Recipients of a kidney transplant\n* Recipients of a primary kidney transplant from a heart-beating deceased, living unrelated or non-HLA identical living related donors.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Multi-organ transplant recipients or prior kidney transplant.\n* Recipients of an organ from a non-heart beating donor.\n* Recipient of an organ from an HLA identical living related donor.\n* ABO incompatible or complement-dependent lymphocytotoxic (CDC) crossmatch positive transplant\n* Recipients of kidneys from donors who are older than 65 years.\n* Recipients of kidneys from donors with terminal serum creatinine > 2 mg/dL.\n* Patients at high immunological risk for rejection\n* Patient who is anti-HIV positive, HBsAg-positive or anti-HCV positive (without proof of sustained viral response (SVR) after anti-HCV treatment).\n* Recipient of a kidney from a donor who tests positive for HIV, HBsAg/HBc positive or HCV.\n* A negative Epstein Barr virus (EBV) test.\n* Evidence of advanced liver disease (Child-Pugh C), or any sign of liver decompensation.\n* Patient with severe systemic infections, current or within the two weeks prior to randomization.\n* History of malignancy of any organ system, treated or untreated, within the past 5 years, regardless of whether there is evidence of local recurrence or metastases, with the exception of localized excised non-melanomatous skin lesions.",
    "miscellaneous_criteria": ""
}